Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CPT1A | P50416 | 2/20 | 0.39 |
| ▸ | CPT1B | Q92523 | 2/20 | 0.39 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5217930 | 0.82 | KCNJ6 (0.48) | MAPTLMNASMN1; SMN2RAB9APOLB | |
| SCHEMBL5216421 | 0.81 | LPAR1 (0.52) | MAPTLMNASMN1; SMN2L3MBTL1CPT1A | |
| SCHEMBL5220598 | 0.81 | HSD17B10 (0.50) | MAPTLMNASMN1; SMN2RAB9APOLB | |
| SCHEMBL5221118 | 0.80 | LPAR1 (0.51) | L3MBTL1POLBMEN1KMT2A | |
| SCHEMBL5219606 | 0.79 | MAPT (0.44) | MAPTLMNASMN1; SMN2TP53RAB9A | |
| SCHEMBL27714640 | 0.78 | MAPT (0.43) | MAPTLMNASMN1; SMN2TP53RAB9A | |
| SCHEMBL5219012 | 0.78 | L3MBTL1 (0.45) | MAPTLMNASMN1; SMN2L3MBTL1MEN1 | |
| SCHEMBL5218299 | 0.78 | MAPT (0.53) | MAPTLMNASMN1; SMN2L3MBTL1TP53 | |
| SCHEMBL5217998 | 0.77 | BLM (0.50) | MAPTLMNASMN1; SMN2RAB9APOLB | |
| SCHEMBL5215989 | 0.77 | MAPT (0.63) | MAPTLMNASMN1; SMN2L3MBTL1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1809380-A2 | INHIBITORS OF HIV-1 CAPSID FORMATION: SUBSTITUTED ARYL AMINOMETHYL THIAZOLE UREAS AND ANALOGUES THEREOF | Achillion Pharmaceuticals, Inc. (US) | 2007-07-25 | — | — | EP | claimed |
| US-7183300-B2 | Inhibitors of HIV-1 capsid formation: substituted aryl aminomethyl thiazole ureas and analogues thereof | UNIVERSITY OF MARYLAND BALTIMORE COUNTY | 2007-02-27 | — | — | US | claimed |
| WO-2006053323-A2 | INHIBITORS OF HIV-1 CAPSID FORMATION: SUBSTITUTED ARYL AMINOMETHYL THIAZOLE UREAS AND ANALOGUES THEREOF | ACHILLION PHARMACEUTICALS, INC. (US) | 2006-05-18 | — | — | WO | claimed |
| US-20060100232-A1 | Inhibitors of HIV-1 capsid formation: substituted aryl aminomethyl thiazole ureas and analogues thereof | ACHILLION PHARMACEUTICAL, INC. | 2006-05-11 | — | — | US | claimed |
| US-7183300-B2 | Inhibitors of HIV-1 capsid formation: substituted aryl aminomethyl thiazole ureas and analogues thereof | UNIVERSITY OF MARYLAND BALTIMORE COUNTY | 2007-02-27 | — | — | US | disclosed |
| US-7183300-B2 | Inhibitors of HIV-1 capsid formation: substituted aryl aminomethyl thiazole ureas and analogues thereof | UNIVERSITY OF MARYLAND BALTIMORE COUNTY | 2007-02-27 | — | — | US | disclosed |
| US-7183300-B2 | Inhibitors of HIV-1 capsid formation: substituted aryl aminomethyl thiazole ureas and analogues thereof | UNIVERSITY OF MARYLAND BALTIMORE COUNTY | 2007-02-27 | — | — | US | disclosed |
| US-20060100232-A1 | Inhibitors of HIV-1 capsid formation: substituted aryl aminomethyl thiazole ureas and analogues thereof | ACHILLION PHARMACEUTICAL, INC. | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100232-A1 | Inhibitors of HIV-1 capsid formation: substituted aryl aminomethyl thiazole ureas and analogues thereof | ZC3HAV1, CD4, ACIN1 | MAPT 420/4885LMNA 2002/4885SMN1; SMN2 3606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.